Article
Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
JAMA oncology - 1 Jul 2020
Miyamoto Shingo, Azuma Koichi, Ishii Hidenobu, Bessho Akihiro, Hosokawa Shinobu, Fukamatsu Nobuaki, Kunitoh Hideo, Ishii Mari, Tanaka Hiroshi, Aono Hiromi, Nakahara Yoshiro, Kusaka Kei, Hosomi Yukio, Kikuchi Norihiro, Mori Yoshiaki, Itani Hidetoshi, Hamada Akinobu, Yamada Kazuhiko, Okamoto Hiroaki
Abstract excerpt
Importance: Although the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for EGFR gene mutation-positive non-small cell lung cancer is well established, optimal dosing remains to be established, especially in elderly or frail patients. Objective: To investigate the efficacy and safety of low-dose erlotinib in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.